Connect Build & Discover Opportunities At ReLeaf Genetics' Summit

ReLeaf Genetics, a science/genetics company based in Atlanta, Georgia, has announced the upcoming ReLeaf Medical Cannabis Summit, will be held on September 28, 2019. In this event, attendees are expected to connect with other leaders of the cannabis industry, build their business, and discover new products, opportunities and the movement. More about this event can be found at https://releafcon.com/about-the-event.

Drew Maloney, CEO of ReLeaf Genetics, says, “We hope that this summit will help propel the industry, increasing its growth even further and expanding it to reach new limits. We believe that nothing but positive things can come out of getting this many individuals together for an event of this scope. We are excited to see what comes out of it and will be eagerly expecting the development of the industry in upcoming months.”

The summit will be composed of product demonstrations, educational seminars, and displays for CBD/THC brands. Through the product demonstrations, attendees will be able to gain a better understanding of the revolutionary medical cannabis industry. The educational seminar will offer informational sessions regarding the medicinal applications of cannabidiol (CBD) and cannabis, including ways to consume CBD in a safe manner, and several cannabis and health related topics.

Real Housewives of Atlanta, America's Next Top Model, Rickey Smiley Morning Show castmate and radio/tv star Eva Marcille Sterling will hold her official product launch party for her upcoming CBD brand that night after the ReLeaf Medical Cannabis Summit. The product launch will be held after The Summit in the top-floor Altitude room of the W Hotel in Midtown Atlanta from 7p to midnight. The ReLeaf Genetics team has played an incremental role in ensuring her brand is driven by science-based research as it proves to be the preferred top-shelf CBD brand offering the natural healthy alternative to various treatments. Many prominent physiVIPs and influential guests are expected to attend both the Summit and the product launch on the 28th of September. Tickets can be purchased at https://releafcon.com/shop-releaf/.

Meanwhile, Rhyan Walcott, Director of Operations for ReLeaf Genetics, explains the importance of the event for businesses. He says, “For a business in the growth stage, to be recognized and known by the important individuals which will be present at the summit is very valuable. We hope our attendees will be able to take advantage of the room full of potential business opportunities that we will have throughout the event.”

Meanwhile, the challenges and opportunities for the medical cannabis industry have been discussed in a blog post by ReLeaf Genetics that can be found at https://releafcon.com/medical-cannabis-poses-challenges-opportunities/. The article reveals that on June 25, 2019, the FDA approved the CBD oral solution Epidiolex for the treatment of seizures that are linked to two severe pediatric epilepsy disorders. This was an important milestone because it was the first FDA-approved drug that contains pure CBD, which is a non-psychoactive substance derived from cannabis.

However, the article also noted that clinical research on cannabis for treating certain health conditions like anxiety, pain, and multiple sclerosis, has been slow. This is due to the legal restrictions that scientists have to face when they perform research on cannabis. FDA Commissioner Dr. Scott Gottlieb had stated that like any other drug, there has to be a comprehensive research on whether a new compound is safe, effective, correctly dosed, and appropriate for treating specific medical conditions.

However, scientists have to overcome several federal regulatory obstacles when studying cannabis and its components. One such barrier is that marijuana is classified as a Schedule I drug. Such drugs are considered to have a high potential for abuse and are not accepted for medical applications. For instance, Epidiolex, despite having been approved by the FDA for treating epileptic seizures, will still need to be rescheduled by the Drug Enforcement Agency (DEA) from Schedule I before doctors can prescribe it as a pharmaceutical product.

Cannabis researchers also face the obstacle of inadequate cannabis supply. Since 1968, the University of Mississippi is the only contractor that has been authorized by the National Institute of Drug Abuse to produce marijuana that can be used for medical research. This limits the ability of researchers to use various strains and quality of cannabis that may be required to address certain questions in their research.

While the DEA had modified its policy two years ago, allowing other facilities to cultivate marijuana, advocates of the medical use of cannabis are worried that the Department of Justice will prevent the DEA from approving the more than 25 applications that have been submitted after the DEA had changed its policy. The DEA has not yet approved a single application.

These federal regulatory obstacles represent the primary challenges that the medical cannabis industry is facing. Unless more scientifically rigorous research on cannabis can be conducted, both the benefits and risks of cannabis and its derivatives will remain unclear.

Those challenges and opportunities will be discussed at the upcoming summit. People who would like to know more about the summit can can check out the company website.